Work

Volumetric Tumor Response and Progression in EGFR-mutant NSCLC Patients Treated with Erlotinib or Gefitinib

Year: 2016

Type: article

Study design: Observational Study

Source: Academic Radiology

DOI: 10.1016/j.acra.2015.11.005

Authors: Mizuki Nishino, Suzanne E. Dahlberg, Linnea E. Fulton, Subba R. Digumarthy, Hiroto Hatabu, Bruce E. Johnson, Lecia V. Sequist

Institutions: Brigham and Women's Hospital, Harvard University, Dana-Farber Cancer Institute, Dana-Farber/Harvard Cancer Center, Dana-Farber Brigham Cancer Center, Massachusetts General Hospital

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: National Institutes of Health, Genentech, National Cancer Institute

Awards: G1702080553, G2645803428, G4310455898, CT Volume Measurement of Lung Cancer treated with Erlotinib: Genomic Correlation, G458608165, G7495787839, G8276505917, G8691211841, G9000031629, G9000107713

OpenAlex ID: W2224970622

FWCI: 5.029

Cites: 46

Cited by: 35

Related to: 10